Company / Capital Expenditures
Abbott Laboratories Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$2.2B
FY2025
5-year range
$1.6B / $2.2B
FY2021-FY2025
Trend
-1.6%
vs FY2024
Sector context
#4 of 151
Health Care
What the data says
Among 151 Health Care companies, Abbott Laboratories is in the top 3% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $1.1B in FY2016 to $2.2B in FY2024.
Based on SEC 10-K filings.
$2.2B in FY2025 with a 5-year CAGR of +9.3%. Top quartile in the Health Care sector.
Improved from $1.9B to $2.2B over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -0.1%
- 5-Year CAGR
- +9.3%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 151This company $2.2B Sector average $271.7M
▼
+699.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +9.3%, indicating consistent growth.
- In FY2025, capital expenditures decreased 1.6% year-over-year.
- Ranks #4 out of 151 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.2B | -1.6% |
| FY2024 | $2.2B | +17.1% |
| FY2023 | $1.9B | -13.4% |
| FY2022 | $2.2B | +32.9% |
| FY2021 | $1.6B | +17.5% |
| FY2020 | $1.4B | -14.9% |
| FY2019 | $1.6B | +46.1% |
| FY2018 | $1.1B | +1.0% |
| FY2017 | $1.1B | +3.1% |
| FY2016 | $1.1B | -5.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026